The chief of the Multiple Sclerosis Division at the Perelman School of Medicine, University of Pennsylvania, discussed recommendations for COVID-19 vaccination in this patient population, specifically for those on disease-modifying therapies. [WATCH TIME: 2 minutes]
Mona Bostick, RDN, LDN, MSCS, gave her perspective on nutrition in MS, popular elimination diets, and the role registered dietitians can play in the multidisciplinary care model.
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 5, 2021.
The director of the Multiple Sclerosis Achievement Center outlined the design of the wellness programs, which are held in 2 different formats. [WATCH TIME: 4 minutes]
Expert clinicians offer their perspectives on the ongoing shortage of neurologists, stigmas associated with migraine, diets for those with epilepsy, mesenchymal stem cells in MS, and other topics.
Robert Fox, MD, discussed what’s currently available in terms of cannabis-derived medications that treat symptoms of multiple sclerosis, and realistic possibility of another soon entering the market.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Victor Sung, MD.
Repeated analyses using both 3-mm and 1-mm diameter macular data—narrower volumes than standard—showed no relevant outer plexiform layer or outer nuclear layer thinning in those with seropositive AQP4-IgG.
Amit Bar-Or, MD, FRCPC, FAAN, FANA, commented on his presentations at CMSC 2021, one of which focused on COVID-19 vaccination, which experts do not believe poses risks for those on disease-modifying therapies.
The staff member at the Mellen Center for Multiple Sclerosis discussed reasons why patients may stop treatment, as well as strategies for maintaining communication with the healthcare team in the event of discontinuation. [WATCH TIME: 5 minutes]
Performing physical activity after receiving a diagnosis of Parkinson disease was associated with a decreased mortality rate, even in individuals with PD who were physically inactive before diagnosis.
An expert provided thoughts on the state of multiple sclerosis research, where the efforts have been directed recently, and areas that need increased focus.
Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.
The Renew Biosciences device is designed to enhance circulation and improve cerebrovascular health by stimulating the physiological effects of exercise and the function of endothelial cells.
Brian Hutchinson, PT, MSCS, commented on the Multiple Sclerosis Achievement Center program, which includes patient data spanning a 3-year period.
The associate professor of pediatrics and neurology at Rutgers–Robert Wood Johnson Medical School commented on the need to recognize when adolescent patients are ready to learn more about their condition. [WATCH TIME: 5 minutes]
Through 36 weeks of treatment with CNM-Au8, investigators observed a slowing of disease progression and decreased number of participants with a 6-point decline on ALSFRS-R.
An expert discussed the ways the multiple sclerosis community can create change and ultimately improve education on cannabis use.
The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health provided context on the EXPAND study, which evaluated treatment efficacy and safety in older and younger patients on siponimod (Mayzent; Novartis).
Investigators interviewed 20 community neurologists about the impact of the pandemic on their professional and personal lives, finding 4 main themes among their responses.
Vikram Bhise, MD, outlined useful questions to include in conversation when discussing the transition to adulthood for patients with pediatric multiple sclerosis.
The professor of neurology at Beth Israel Deaconess Medical Center discussed the treatment potential of melanin concentrating hormone receptor 1 antagonists for narcolepsy. [WATCH TIME: 3 minutes]
In a phase 2/3 setting, AMX0035 demonstrated a 44% lower risk of death for patients with ALS compared to those who started on placebo.
An expert provides the necessary steps needed to bolster accuracy of prescribed disease-modifying therapies for MS and do away with outdated trial-and-error approaches.
Three (20%) patients with Dravet syndrome had increases in seizure frequency after the first vaccine dose; however, no such increase was observed after the second dose.
Vikram Bhise, MD, discussed findings recently presented at CMSC 2021, where teenagers with multiple sclerosis were interviewed to identify perceptions of QOL during the transition to adulthood.
Research on advanced therapies and immune systems have helped clinicians understand more about how to improve treatments for multiple sclerosis.
The founder of Food Matters 365, in Greensboro, North Carolina, commented on the benefits of adding a dietitian to the healthcare team for patients with multiple sclerosis. [WATCH TIME: 3 minutes]
An abnormal composite outcome of death or disability at age 18 to 22 months was found in 46% of those who had seizures during rewarming compared with 25% of those without seizures at rewarming.
An expert provided context on the need to improve awareness and education on cannabis for patients with multiple sclerosis.
